Phenotypic studies of natural killer cell subsets in human transporter associated with antigen processing deficiency

PLoS ONE

Volumn 2, Issue 10, 2007, Pages

  Zimmer, Jacques ^a   Bausinger, Huguette ^b,c,d   Andrès, Emmanuel ^e   Donato, Lionel ^e   Hanau, Daniel ^b,c,d   Hentges, François ^a   Moretta, Alessandro ^f   de la Salle, Henri ^b,c,d  

^a LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^b INSERM   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d Etab Francais du Sang Alsace   (France)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^f UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; CD94 ANTIGEN; CHROMIUM 51; FLUOROCHROME; NATURAL KILLER CELL RECEPTOR NKG2A; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; ABC TRANSPORTER; CHROMIUM; DIAGNOSTIC AGENT; FC RECEPTOR; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING (TAP); UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIGEN PRESENTATION; ARTICLE; BRONCHIECTASIS; CELL EXPANSION; CELL ISOLATION; CELLULAR DISTRIBUTION; CHRONIC INFLAMMATION; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; LEUKOCYTOCLASTIC VASCULITIS; LYMPHOCYTE SUBPOPULATION; MALE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PNEUMOCONIOSIS; PRESCHOOL CHILD; VASCULITIS; AUTOIMMUNE DISEASE; BIOLOGICAL MODEL; BIOSYNTHESIS; BLOOD; CYTOLOGY; CYTOTOXICITY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MONONUCLEAR CELL; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANTIGEN PRESENTATION; ANTIGENS, CD56; ATP-BINDING CASSETTE TRANSPORTERS; AUTOIMMUNE DISEASES; BIOLOGICAL TRANSPORT; CHROMIUM RADIOISOTOPES; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MODELS, BIOLOGICAL; PHENOTYPE; RECEPTORS, IGG;

EID: 42049087470     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001033     Document Type: Article

References (44)

1. Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22: 633-640.
2. Mavilio D, Lombardo G, Benjamin J, Kim D, Follman D, et al. (2005) Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci USA 102: 2886-2891.
3. Smyth MJ, Hayakawa Y, Takeda K, Yagita H (2002) New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Immunol 2: 850-861.
4. Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23: 225-274.
5. O'Connor GM, Hart OM, Gardiner CM (2006) Putting the natural killer cell in its place. Immunology 117: 1-10.
6. Kumar V, McNerney ME (2005) A new self: MHC-class-I-independent natural-killer-cell self-tolerance. Nat Rev Immunol 5: 363-374.
7. Grommé M, Neefjes J (2002) Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways. Mol Immunol 39: 181-202.
8. Pamer E, Cresswell P (1998) Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol 16: 323-358.
9. York IA, Rock KL (1996) Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 14: 369-396.
10. De la Salle H, Donato L, Zimmer J, Plebani A, Hanau D, et al. (1999) HLA class I deficiencies. In: Ochs HD, Smith CIE, Puck JM, eds. Primary Immunodeficiency Diseases: a molecular and genetic approach. New York: Oxford University Press. pp 181-188.
11. Zimmer J, Andrès E, Donato L, Hanau D, Hentges F, et al. (2005) Clinical and immunological aspects of HLA class I deficiency. QJM 98: 719-727.
12. De la Salle H, Hanau D, Fricker D, Urlacher A, Kelly A, et al. (1994) Homozygous human TAP peptide transporter mutation in HLA class I deficiency. Science 265: 237-241.
13. Donato L, de la Salle H, Hanau D, Tongio MM, Oswald M, et al. (1995) Association of HLA class I antigen deficiency related to a TAP2 gene mutation with familial bronchiectasis. J Pediatr 127: 895-900.
14. Donato L, de la Salle H, Hanau D, Albrech C, Oswald M, et al. (1997) Déficit en antigènes HLA de classe I et bronchiectasies familiales: revue de la littérature avec étude clinique et biologique. Rev Fr Allergol 37: 127-134.
15. De la Salle H, Zimmer J, Fricker D, Angenieux C, Cazenave JP, et al. (1999) HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1. J Clin Invest 103: R9-R13.
16. Furukawa H, Murata S, Yabe T, Shimbara N, Keicho N, et al. (1999) Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome. J Clin Invest 103: 755-758.
17. Maeda H, Hirata R, Chen RF, Suzaki H, Kudoh S, et al. (1985) Defective expression of HLA class I antigens: a case of the bare lymphocyte syndrome without immunodeficiency. Immunogenetics 21: 549-558.
18. Plebani A, Monafo V, Cattaneo R, Carella G, Brugnoni D, et al. (1996) Defective expression of HLA class I and CD1a molecules in boy with Marfan-like phenotype and deep skin ulcers. J Am Acad Dermatol 35: 814-818.
19. Matamoros N, Milà J, Llano M, Balas A, Vicario JL, et al. (2001) Molecular studies and NK cell function of a new case of TAP2 homozygous human deficiency. Clin Exp Immunol 125: 274-282.
20. Markel G, Mussafi H, Ling KL, Salio M, Gadola S, et al. (2004) The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood 103: 1770-1778.
21. De la Salle H, Saulquin X, Mansour I, Klaymé S, Fricker D, et al. (2002) Asymptomatic deficiency in the peptide transporter associated to antigen processing. Clin Exp Immunol 128: 525-531.
22. Parissiadis A, Dormoy A, Fricker D, Hanau D, de la Salle H, et al. (2005) Unilateral necrotising toxoplasmic retinochoroiditis as the main clinical manifestation of a peptide transporter (TAP) deficiency. Br J Ophtalmol 89: 1661-1662.
23. Dogu F, Ikinciogullari A, Fricker D, Bozdogan G, Aytekin C, et al. (2006) A novel mutation for TAP deficiency and its possible association with toxoplasmosis. Parasitol Int 55: 219-222.
24. Zimmer J, Donato L, Hanau D, Cazenave JP, Tongio MM, et al. (1998) Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type I bare lymphocyte syndrome). J Exp Med 187: 117-122.
25. Zimmer J, Donato L, Hanau D, Cazenave JP, Moretta A, et al. (1999) Inefficient protection of human TAP-deficient fibroblasts from autologous NK cell- mediated lysis by cytokines inducing HLA class I expression. Eur J Immunol 29: 1286-1291.
26. Vitale M, Zimmer J, Castriconi R, Bottino C, Donato L, et al. (2002) Analysis of natural killer cells in TAP2-deficient patients: expression of functional triggering receptors and evidence for the existence of inhibitory receptor(s) that prevent lysis of normal autologous cells. Blood 99: 1723-1729.
27. Sivori S, Vitale M, Bottino C, Marcenaro E, Sanseverino L, et al. (1996) CD94 functions as a natural killer cell inhibitory receptor for different HLA class I alleles: identification of the inhibitory form of CD94 by the use of novel monoclonal antibodies. Eur J Immunol 26: 2487-2492.
28. dim NK cells. Eur J Immunol 31: 3121-3126.
29. Robertson MJ, Ritz J (1990) Biology and clinical relevance of human natural killer cells. Blood 76: 2421-2438.
30. Carson W, Caligiuri M (1996) Natural killer cell subsets and development. Methods 9: 327-343.
31. Cac N, Ballas ZK (2006) Recalcitrant warts, associated with natural killer cell dysfunction, treated with systemic IFN-α. J Allergy Clin Immunol 118: 526-528.
32. -natural killer cells in a case of X-SCID with Omenn syndrome-like manifestations. Eur J Haematol 79: 81-85.
33. Nagler A, Lanier LL, Cwirla S, Phillips JH (1989) Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 143: 3183-3191.
34. André P, Spertini O, Guia S, Rihet P, Dignat-George F, et al. (2000) Modification of P-selectin glycoprotein ligand-1 with a natural killer cell-restricted sulfated lactosamine creates an alternate ligand for L-selectin. Proc Natl Acad Sci USA 97: 3400-3405.
35. + NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol 166: 6477-6482.
36. bright subset. Blood 97: 3146-3151.
37. Freud AG, Caligiuri MA (2006) Human natural killer cell development. Immunol Rev 214: 56-72.
38. right NK cells. J Leukoc Biol 80: 1529-1541.
39. bright NK cells. Scand J Infect Dis 38: 1122-1125.
40. Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol. Sci. 28: 121-126.
41. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, et al. (2005) Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436: 709-713.
42. Raulet DH, Vance RE (2006) Self-tolerance of natural killer cells. Nat Rev Immunol 6: 520-531.
43. Anfossi N, André P, Guia S, Falk CS, Roetynck S, et al. (2006) Human NK cell education by inhibitory receptors for MHC class I. Immunity 25: 331-342.
44. Doucey MA, Scarpellino L, Zimmer J, Guillaume P, Luescher IF, et al. (2004) Cis association of Ly49A with MHC class I restricts natural killer cell inhibition. Nat Immunol 5: 328-336.